MedTrace Logo

Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.

NCT00219544 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 158

Last updated 2021-01-22

Study results available
· View outcomes & findings →

Summary

This study will measure the impact of treatment with pregabalin in adult men and women who have a diagnosis of peripheral neuropathic pain (pain caused by a primary lesion of the peripheral nervous system such as Diabetic peripheral Neuropathy and Postherpetic Neuralgia).

Conditions

  • Neuropathic Pain

Interventions

DRUG

Pregabalin (Lyrica)

pregabalin 150mg/day (75mg BID)

DRUG

Pregabalin (Lyrica)

pregabalin 300 mg/day (150mg BID)

DRUG

Pregabalin (Lyrica)

pregabalin 600/day (300mg BID)

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00219544 on ClinicalTrials.gov